

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/524,738
				Filing Date	September 15, 2005
				First Named Inventor	Steffen Goletz
				Art Unit	1642
				Examiner Name	Aeder, Sean E.
Sheet	1	of	2	Attorney Docket Number	10913.0001-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		US-2006/0292129 A1	12-28-2006	Goletz, Steffen, et al	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 9740182 A	10-30-1997	Pecher, Gabriele		
		WO 2004009632 A	01 29-2004	Goltez, Steffen et al.		
		WO 2004018659 A	03-04-2004	Glycotope GmbH		
		WO 94/29469	12-22-1994	Vical Incorporated et al		
		WO 97/00957	01-09-1997	Patterson-Winston, Campbell et al		
		WO 03/023023	08-17-2001	Goletz, Steffen et al		

NONPATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation ⁶	
		AGRAWAL, et al. "Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2.", <i>Naturel. Med.</i> , 4(1):43-9 (1998)		
		ANDERSON. "Human Gene Therapy". Science, Vol. 256, pp. 808-813, (1992).		
		BÖHM et al., "Carbohydrate Recognition on MUC1-Expressing Targets Enhances Cytotoxicity of a T cell Subpopulation", <i>Scandinavian Journal of Immunology</i> , vol. 46, no. 1, pages 27-34, XP-002323076 (1997)		
		BRUMMELKAMP, et al. "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells". Science, Vol. 296, pp. 550-553, (2002).		
		DALL'OLIO, et al., "Expression of beta-galactoside alpha 2,6-sialyltransferase does not alter the susceptibility of human colon cancer cells to NK-mediated cell lysis." <i>Glycobiology</i> . 7:507-513 (1997)		
		DUK et al., "Purification of Human Anti-TF (Thomsen-Friedenreich) and Anti-Tn Antibodies by Affinity Chromatography on Glycophorin A Derivatives and Characterization of the Antibodies by Microtiter Plate ELISA", <i>Archivum Immunologiae et Therapiae Experimentalis</i> , vol. 46, no. 2, pages 69-77, XP-008045186, (1998)		
		ELBASHIR, et al. "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells". <i>Nature</i> , Vol. 411, pp. 494-498, (2001).		
		GOLLASCH et al., "Identification of Immunogenic Peptide-Mimics for the Thomsen-Friedenreich-Glycoantigen", <i>Annals of Hematology, Berlin, DE</i> , vol. 77, no. suppl. 2, page S84, XP-000960533, (1998)		
		ICHIYAMA, "Induction of Non-HLA-restricted Anti-tumour Effector Cells with Strong Cytotoxic Activity Using MUC1/B7 Cotransfected K562 Cells", <i>Cell Resource Center for Biomedical Research, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan</i> , vol. 51, no. 3-4, pages 93-110, XP-001182213, (2000)		
		ISNER, et al. "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb". <i>The Lancet</i> , Vol. 348, pp. 370-374, (1996).		
		KARSTEN et al., "Enhanced Binding of Antibodies to the DTR Motif of MUC1 Tandem Repeat Peptide is Mediated by Site-Specific Glycosylation", <i>Cancer Research, American Association for Cancer Research, Baltimore, MD, US</i> , vol. 58, no. 12, pages 2541-2549, XP-002112486, (June 15, 1998)		
		KUNZ, "Synthetic Glycopeptides for the Development of Tumour-selective Vaccines", <i>Journal of Peptide Science: an Official Publication of the European Peptide Society</i> , vol. 9, no. 9, pages 563-573, XP-00845163, (September 2003)		

IDS Form PTO/SB/08: Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/524,738
				Filing Date	September 15, 2005
				First Named Inventor	Steffen Goletz
				Art Unit	1642
				Examiner Name	Aeder, Sean E.
Sheet	2	of	2	Attorney Docket Number	10913.0001-00000

NONPATENT LITERATURE DOCUMENTS			
		NATALI, et al., <i>Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells</i> . Cancer Res 1983; 43:660-668	
		NOVINA, et al. "siRNA-directed inhibition of HIV-1 infection". Nature Medicine, Vol. 8, No. 7, pp. 681-686, (2002)	
		OHYAMA, et al. "Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells". The EMBO Journal, Vol. 18, No. 6, pp. 1516-1525, (1999).	
		OHYAMA, et al. "Natural killer cells attack tumor cells expressing high levels of sialyl Lewis x oligosaccharides". PNAS, Vol. 99, No. 21, pp. 13789-13794., (2002)	
		OUAGARI, et al. "Glycophorin A Protects K562 Cells from Natural Killer Cell Attack". The Journal of Biological Chemistry, Vol. 270, No. 45, pp. 26970-26975, (1995).	
		OWENS, et al. "Identification of two short internal ribosome entry sites selected from libraries of random oligonucleotides". PNAS, Vol. 98, No. 4, pp. 1471-1476, (2001).	
		PADDISON, et al. "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells". Genes & Development, Vol. 16, pp. 948-958, (2002).	
		PAHLSSON, et al., "Biochemical characterization of the O-glycans on recombinant glycophorin a expressed in Chinese hamster ovary cells." <i>Glycoconj. J.</i> , 11:43-50 (1994)	
		SPRINGER, et al., "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy." <i>J. Mol. Med.</i> , 75:594-602 (1997)	
		SIVANANDHAM, et al. "Cancer Vaccines: Clinical Applications". Principles and Practice of the Biologic Therapy of Cancer, Third Edition, S. Rosenberg, pp. 632-647, Lippincott Williams & Wilkins, Philadelphia, PA., (2000)	
		VAN RINSUM, et al., "Specific inhibition of human natural killer cell-mediated cytotoxicity by sialic acid and sialo-oligosaccharides." <i>Int. J. Cancer</i> , 38:915-922 (1986)	
		VERMA, et al. "Gene therapy – promises, problems and prospects". Nature, Vol. 389, pp. 239-242, (1997).	
		Office action dated 1-27-09 from application USSN10/568,098	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO Notes regarding this form:

¹ Applicant's unique citation designation number (optional).

² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**